Clinical Rheumatology

, Volume 38, Issue 2, pp 577–581 | Cite as

On demand use of anakinra for attacks of familial Mediterranean fever (FMF)

  • Hakan BabaogluEmail author
  • Ozkan Varan
  • Hamit Kucuk
  • Nuh Atas
  • Hasan Satis
  • Reyhan Salman
  • Mehmet Akif Ozturk
  • Seminur Haznedaroglu
  • Berna Goker
  • Abdurrahman Tufan
Brief Report


To evaluate the efficacy of on-demand use of anakinra in patients with crFMF. The Gazi FMF cohort was established in the year 2010, and from that date, 689 patients with FMF diagnosed according to the Tel Hashomer criteria were registered. Attack type, duration, severity, and their impact on life were collected either by disease diaries or a mobile phone application (FMF AIDD, AppStore, and Playstore). A retrospective cohort analysis was made from records of patients who have ever been treated with IL-1 inhibitors. A total of 78 patients were treated with IL-1 inhibitors in our cohort. Among these, 15 patients were identified who received on-demand anakinra. Rationale for on-demand use was prominent prodrome or trigger for attacks and patient’s personal claim. Six patients were switched from regular use and nine were directly started as on-demand use. All were using background colchicine in maximum tolerated doses. None of the patients had evidence of persistently elevated acute phase reactants or proteinuria. The median duration of on-demand anakinra use was 6 (3–36) months. Pre- and post- on-demand anakinra periods were compared. Patient reported attack severity (p = 0.002), duration (p = 0.001), frequency (p = 0.001), absenteeism (p = 0.002), and presenteeism (p = 0.002) were significantly improved. On-demand anakinra prevented progression of prodromes to full-blown attacks which was demonstrated by decrease in the rate of attack/prodrome ratio (p = 0.02). On-demand anakinra can be continued in ten subjects on long-term. On-demand anakinra significantly improved FMF attacks in certain patients which suggest this approach would be of benefit in daily practice in selected patients.


Anakinra Familial Mediterranean fever On demand 


Compliance with ethical standards




  1. 1.
    Heller H, Sohar ESL (1958) Familial Mediterranean fever. AMA Arch Intern Med 102:50–71CrossRefGoogle Scholar
  2. 2.
    Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43:227–253CrossRefGoogle Scholar
  3. 3.
    Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror Autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668. CrossRefGoogle Scholar
  4. 4.
    Ben-Chetrit E, Touitou I (2009) Familial Mediterranean fever in the world. Arthritis Rheum 61:1447–1453. CrossRefGoogle Scholar
  5. 5.
    Karadag O, Tufan A, Yazisiz V, Ureten K, Yilmaz S, Cinar M, Akdogan A, Erdem H, Ozturk MA, Pay S, Dinc A (2013) The factors considered as trigger for the attacks in patients with familial Mediterranean fever. Rheumatol Int 33:893–897. CrossRefGoogle Scholar
  6. 6.
    Lidar M, Yaqubov M, Zaks N et al (2006) The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 33:1089–1092Google Scholar
  7. 7.
    Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B, Haznedaroglu S, Onat AM (2011) Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int 31:623–628. CrossRefGoogle Scholar
  8. 8.
    Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146:467–478. CrossRefGoogle Scholar
  9. 9.
    Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, Amselem S, Gershoni-Baruch R, Touitou I, Ben-Chetrit E (2013) Evidence-based recommendations for the practical management of familial Mediterranean fever. Semin Arthritis Rheum 43:387–391. CrossRefGoogle Scholar
  10. 10.
    Lidar M, Scherrmann J-M, Shinar Y et al (2004) Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33:273–282CrossRefGoogle Scholar
  11. 11.
    Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75:644–651. CrossRefGoogle Scholar
  12. 12.
    van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys B, Vanderschueren S (2016) Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics 10:75–80. Google Scholar
  13. 13.
    Ozen S, Kone-Paut I, Gul A (2017) Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum 47:115–120. CrossRefGoogle Scholar
  14. 14.
    Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial Mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 69:854–862. CrossRefGoogle Scholar
  15. 15.
    Grimwood C, Despert V, Jeru I, Hentgen V (2015) On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (United Kingdom) 54:1749–1751. CrossRefGoogle Scholar
  16. 16.
    Bodar EJ, Kuijk LM, Drenth JPH, van der Meer JWM, Simon A, Frenkel J (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70:2155–2158. CrossRefGoogle Scholar
  17. 17.
    Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K (2008) Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 66:489–491Google Scholar
  18. 18.
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885.<1879::AID-ART23>3.0.CO;2-M CrossRefGoogle Scholar
  19. 19.
    Piram M, Koné-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, Stojanov S, Simon A, Finetti M, Sormani MP, Martini A, Gattorno M, Ruperto N (2014) Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 73:2168–2173. CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Department of Internal Medicine, Division of RheumatologyGazi University Faculty of MedicineAnkaraTurkey
  2. 2.Department of Internal Medicine, Division of Rheumatology, Erzurum Regional Research and Training HospitalHealth Science UniversityErzurumTurkey

Personalised recommendations